The world’s first “Artificial Pancreas” will be hitting the market in 2017, as it has been approved by the US Food and Drug Administration (FDA). The MiniMed 670G device combines an automated glucose monitor and an insulin pump. This could help over 1.25 million people in the US with Type 1 diabetes.
The US Food and Drug Administration has finally approved the first “artificial pancreas”, which would immensely help people with Type 1 diabetes all over the world.
The company Medtronic designed the technology, which combines an automated glucose monitor and an insulin pump.
It measures the amount of glucose in the blood, and if it seems to be a bit over the expected amount, it administers an accurate amount of insulin in order to induce glucose intake, and bring the blood glucose level back down to normal.
It would also shut off the insulin release if blood glucose becomes lower than normal.
Medtronic described the device as: “the first hybrid closed loop system in the world.”
“This first-of-its-kind technology can provide people with type 1 diabetes greater freedom to live their lives without having to consistently and manually monitor baseline glucose levels and administer insulin,” says FDA Center for Devices and Radiological Health director Dr. Jeffrey Shuren.
Even though the FDA approved the device for anyone aged 14 and above, Medtronic still wants to conduct additional real-life testing before its launch in spring 2017.
The company also wants to determine the safety of using the device below the age the FDA proposed, since Type 1 diabetes affects young children as well.
In Type 1 diabetes, the pancreas has a problem producing insulin, which naturally controls the amount of glucose in the blood by inducing cells to take in glucose.
An uncontrolled amount of glucose in the blood could cause blindness, prompt kidney failure, heighten risks for cardiovascular disease and many other complications.
According to the American Diabetes Association, 9.3 percent of the population have the disease, and 1.4 million Americans are diagnosed each year.
Therefore, this device provides a lot of hope for solving the problem for Type 1 diabetics, and can be a revolutionary invention.